Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: October 22, 2007

BioAlliance Pharma will present promising in vivo results for a New Entity at 15th Congress of Europ(...)

(Nanowerk News) BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, said today it will present the first promising in vivo results for its New Entity AMEP, invasive melanoma drug candidate (BA 015 program), at the 15th congress of the European Society of Gene and Cell Therapy, Rotterdam, October 27-30.
These research results complement BioAlliance Pharma’s activities in innovative drug delivery methods, which have enabled it to bring a product to market, and carry out clinical programs including three ongoing Phase III trials, while pursuing basic research into new therapeutic targets in HIV and cancer.
The latest results are in the field of oncology where the company has focused on new targets, particularly those implicated in resistance and tumoral invasion (cytoskeleton). The development of AMEP is part of this strategy. AMEP is an anti-angiogenic and anti-proliferative peptide, which binds to the integrins of activated endothelial and cancerous cells.
The Company has developed a plasmid that allows the expression of AMEP in vivo. It will give data on its properties and its anti-tumoral efficacy at the ESGCT congress. AMEP or plasmid AMEP (BA 015 program) is a BioAlliance Pharma drug candidate with potential use against invasive melanoma.
BioAlliance Pharma is collaborating closely with international experts in angiogenesis and oncology at Inserm (Saint Louis Hospital) and the Institut Gustave Roussy. “BioAlliance’s work with Inserm and the IGR is an excellent example of the company’s academic alliances’ with the major French research laboratories focusing on human health,” said Professor Christian Auclair, CSO at BioAlliance Pharma. “These alliances give the company continued access to cutting edge science.”
Two patent families protect this program internationally as part of BioAlliance Pharma’s vigorous intellectual property policy.
About BioAlliance Pharma
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance. The Company is currently conducting 3 phase III clinical trials on innovative products. Two products are based on the Lauriad® mucoadhesive technology, which allows an early and prolonged release of therapeutic agents at the site of the disease: one authorized product in France and two clinical international phase III trials ongoing (Loramyc® and acyclovir Lauriad®). One product is based on the Transdrug® nanoparticle technology designed specifically for intracellular targeting: one international phase III trial ongoing on primary liver cancer (doxorubicin Transdrug®). The company develops also a New Entities program focused on new targets in oncology and HIV. The company concluded two strategic partnerships in 2007 to sell its Loramyc® product in Europe and in the US. BioAlliance Pharma has just announced the launch of Loramyc® on the French market.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website www.amf-france.org or BioAlliance Pharma S.A.’s website www.bioalliancepharma.com.
For press release and other company information, visit www.bioalliancepharma.com.
Source: BioAlliance Pharma